Panthera has started vaccinating volunteers in Valneva’s double-blind, phase three, COVID prevention trial. The trial will compare Valneva’s inactivated vaccine, VLA2001, with AstraZeneca’s conditionally approved vaccine Vaxzeria. Unlike earlier COVID-19 vaccine trials, which involved a placebo dose, everyone involved in this study will receive two active vaccine doses....
Panthera’s clinical trial sites in Preston, North Manchester and North London began dosing volunteers in the Phase III PROVENT trial which will evaluate AstraZeneca’s long-acting antibody combination, AZD7442, for the potential prevention of COVID-19. The double-blind, placebo-controlled trial will include adult volunteers who have no history of COVID-19 and have an increased risk of infection...
Independent Site Management Organisation Panthera is working with sponsors who need to press ahead with trials which can be done safely. “The safety of clinical trial patients and staff is paramount. We are working with our clients in pharma and CROs to assess each trial to see if it needs to be suspended, delayed or if it can carry on in a way that is safe both for the clinicians and participants” commented Stuart Young CEO...
Panthera has started vaccinating volunteers in Valneva’s double-blind, phase three, COVID prevention trial. The trial will compare Valneva’s inactivated vaccine, VLA2001, with AstraZeneca’s conditionally approved vaccine Vaxzeria. Unlike earlier COVID-19 vaccine trials, which involved a placebo dose, everyone involved in this study will receive two active vaccine doses....
Panthera’s clinical trial sites in Preston, North Manchester and North London began dosing volunteers in the Phase III PROVENT trial which will evaluate AstraZeneca’s long-acting antibody combination, AZD7442, for the potential prevention of COVID-19. The double-blind, placebo-controlled trial will include adult volunteers who have no history of COVID-19 and have an increased risk of infection...
Independent Site Management Organisation Panthera is working with sponsors who need to press ahead with trials which can be done safely. “The safety of clinical trial patients and staff is paramount. We are working with our clients in pharma and CROs to assess each trial to see if it needs to be suspended, delayed or if it can carry on in a way that is safe both for the clinicians and participants” commented Stuart Young CEO...